Abstract
BACKGROUND AND PURPOSE: The standard for evaluating interval radiologic activity in MS, side-by-side MR imaging comparison, is restricted by its time-consuming nature and limited sensitivity. VisTarsier, a semiautomated software for comparing volumetric FLAIR sequences, has shown better disease-activity detection than conventional comparison in retrospective studies. Our objective was to determine whether implementing this software in day-to-day practice would show similar efficacy.
MATERIALS AND METHODS: VisTarsier created an additional coregistered image series for reporting a color-coded disease-activity change map for every new MS MR imaging brain study that contained volumetric FLAIR sequences. All other MS studies, including those generated during software-maintenance periods, were interpreted with side-by-side comparison only. The number of new lesions reported with software assistance was compared with those observed with traditional assessment in a generalized linear mixed model. Questionnaires were sent to participating radiologists to evaluate the perceived day-to-day impact of the software.
RESULTS: Nine hundred six study pairs from 538 patients during 2 years were included. The semiautomated software was used in 841 study pairs, while the remaining 65 used conventional comparison only. Twenty percent of software-aided studies reported having new lesions versus 9% with standard comparison only. The use of this software was associated with an odds ratio of 4.15 for detection of new or enlarging lesions (P = .040), and 86.9% of respondents from the survey found that the software saved at least 2–5 minutes per scan report.
CONCLUSIONS: VisTarsier can be implemented in real-world clinical settings with good acceptance and preservation of accuracy demonstrated in a retrospective environment.
ABBREVIATIONS:
- AIC
- akaike information criterion
- CSSC
- conventional side-by-side comparison
- EDSS
- Expanded Disability Status Scale
- VT
- VisTarsier
Footnotes
Disclosures: Tomas Kalincik—UNRELATED: Board Membership: Roche, Sanofi Genzyme, Novartis, Merck, Biogen; Consultancy: Novartis, Biogen, Merck, brain atrophy initiative by Sanofi Genzyme; Grants/Grants Pending: National Health and Medical Research Council, Medical Research Future Fund, Australian Research Council, MS Research Australia, Eugène Devic EDMUS Foundation/Association pour la Recherche contre la Sclérose en Plaques, Multiple Sclerosis International Federation, Biogen; Payment for Lectures Including Service on Speakers Bureaus: WebMD Global, Novartis, Biogen, Sanofi Genzyme, Teva Pharmaceutical Industries, BioCSL, Merck; Payment for Development of Educational Presentations: WebMD Global, Novartis, Biogen, Sanofi Genzyme, Teva Pharmaceutical Industries, BioCSL, Merck; Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: WebMD Global, Novartis, Biogen, Sanofi Genzyme, Teva Pharmaceutical Industries, BioCSL, Merck. Frank Gaillard—UNRELATED: Grant: Royal Melbourne Hospital Foundation, Comments: The grant was internal (Royal Melbourne Hospital raises funds to support local projects) and was awarded to continue development of VisTariser software, make it available under an open-source license, and perform this prospective validation. No external funding was received for this project*; OTHER RELATIONSHIPS: Founder CEO of Radiopedia.org. *Money paid to the institution.
- © 2019 by American Journal of Neuroradiology